Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2001 Jun;158(6):1955-9.
doi: 10.1016/S0002-9440(10)64665-2.

Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors

C Billerey  1 , D Chopin, M H Aubriot-Lorton, D Ricol, S Gil Diez de Medina, B Van Rhijn, M P Bralet, M A Lefrere-Belda, J B Lahaye, C C Abbou, J Bonaventure, E S Zafrani, T van der Kwast, J P Thiery, F Radvanyi
Affiliations

Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors

C Billerey et al. Am J Pathol. 2001 Jun.

Abstract

We recently identified activating mutations of fibroblast growth factor receptor 3 (FGFR3) in bladder carcinoma. In this study we assessed the incidence of FGFR3 mutations in a series of 132 bladder carcinomas: 20 carcinoma in situ (CIS), 50 pTa, 19 pT1, and 43 pT2-4. All 48 mutations identified were identical to the germinal activating mutations that cause thanatophoric dysplasia, a lethal form of dwarfism. The S249C mutation, found in 33 of the 48 mutated tumors, was the most common. The frequency of mutations was higher in pTa tumors (37 of 50, 74%) than in CIS (0 of 20, 0%; P < 0.0001), pT1 (4 of 19, 21%; P < 0.0001) and pT2-4 tumors (7 of 43, 16%; P < 0.0001). FGFR3 mutations were detected in 27 of 32 (84%) G1, 16 of 29 (55%) G2, and 5 of 71 (7%) G3 tumors. This association between FGFR3 mutations and low grade was highly significant (P < 0.0001). FGFR3 is the first gene found to be mutated at a high frequency in pTa tumors. The absence of FGFR3 mutations in CIS and the low frequency of FGFR3 mutations in pT1 and pT2-4 tumors are consistent with the model of bladder tumor progression in which the most common precursor of pT1 and pT2-4 tumors is CIS.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
FGFR3 mutations according to stage or grade. a: Percentage of FGFR3 mutations in carcinoma in situ, pTa, pT1, and pT2–4 tumors. b: Percentage of mutations as a function of tumor grade.
See this image and copyright information in PMC

References

    1. Lee R, Droller MJ: The natural history of bladder cancer: implications for therapy. Urol Clin N Am 2000, 27:1-13 - PubMed
    1. Spruck CH, Ohneseit PF, Gonzalez-Zulueta M, Esrig D, Miyao N, Tsai YC, Lerner SP, Schmútte C, Yang AS, Cote R, Dubeau L, Nichols PW, Hermann GG, Steven K, Horn T, Skinner DG, Jones PA: Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994, 54:784-788 - PubMed
    1. Reznikoff CA, Belair CD, Yeager TR, Savelieva E, Blelloch RH, Puthenveettil JA, Cuthill S: A molecular genetic model of human bladder cancer pathogenesis. Semin Oncol 1996, 23:571-584 - PubMed
    1. Cairns P, Sidransky D: Bladder cancer. Vogelstein B Kinzler KW eds. The Genetic Basis of Human Cancer. 1998, :pp 639-645 McGraw-Hill, New York
    1. Cordon-Cardo C: Molecular alterations in bladder cancer. Cancer Surv 1998, 32:115-131 - PubMed

Publication types

MeSH terms

Substances